Navigation Links
Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning

EAST NORRITON, Pa., July 23 /PRNewswire/ -- Tengion Inc., a clinical stage biotechnology company focused on the development of neo-organs and neo-tissues, today announced that it has appointed Mark Stejbach as Vice President, Marketing and Commercial Planning. Mr. Stejbach brings more than twenty years of marketing, sales, finance, and managed care experience from both Merck & Co., Inc. and Biogen, Inc.

"We are very pleased to welcome Mark to the Tengion executive team as we are advancing our Neo-Bladder clinical trial programs along with commercial planning activities," said Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion. "Mark brings extensive experience and a proven track record in both large pharma and biotech, including the successful launch of AVONEX for multiple sclerosis. His broad expertise in managing commercial activities across all stages of product development, and in specialty markets, will provide key insights to Tengion as we continue to grow and move our clinical pipeline toward commercialization in the US and Europe."

Mr. Stejbach started his pharma career at Merck in 1987 and went on to lead marketing campaigns for VASOTEC and PROSCAR. From 1994 to 1997, Mr. Stejbach worked for Biogen, Inc. developing and executing the launch marketing plan for the company's highly successful first marketed product, AVONEX, for multiple sclerosis. He then rejoined Merck in 1997 and since that time has held numerous senior leadership positions within the company including Senior Director roles in market development, specialty sales, marketing, and investor relations; and Vice President, Sales Services prior to his most recent role of Vice President of Managed Care Marketing in Merck's United States Pharmaceutical division. Mr. Stejbach earned his MBA from The Wharton School, University of Pennsylvania, and a BS in mathematics from Virginia Tech. He was recently named a 2008 Emerging Pharma Leader by Pharmaceutical Executive magazine.

"I am thrilled to join Tengion at what is an extremely exciting time for the company," commented Mr. Stejbach. "As Tengion continues to advance its Neo-Bladder Augment, Conduit and Replacement programs, I look forward to helping the Company achieve its ultimate goal of successfully bringing unique and compelling medical advances to patients in need."

About Tengion

Tengion, a clinical stage biotechnology company, focuses on developing, manufacturing and commercializing human neo-organs and neo-tissues using our Autologous Organ Regeneration Platform(TM). Tengion uses biocompatible materials and a patient's own (autologous) cells to create a functional neo-organ or neo-tissue that is designed to catalyze the body's innate ability to regenerate. Tengion's product candidates may ultimately address the most critical problems facing organ and tissue failure patients, enabling people to lead healthier lives without donor transplants or the side effects of related therapies.

SOURCE Tengion Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Tengion Announces European Orphan Drug Designation for Neo-Bladder Augment
2. Tengion Appoints Jeff Randall to Board of Directors
3. Tengion to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
4. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
5. Innocoll Appoints Anthony H. Wild Ph.D. to Its Board of Directors
6. AMT Appoints Director Global Marketing and Sales
7. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
8. WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy
9. PharmAthene Appoints Jordan P. Karp, J.D. Senior Vice President and General Counsel
10. Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer
11. Transcept Pharmaceuticals Appoints Key Senior Executives
Post Your Comments:
(Date:6/27/2016)... SAN DIEGO , June 27, 2016  Sequenom, ... company committed to enabling healthier lives through the development ... Supreme Court of the United States ... Federal courts that the claims of Sequenom,s U.S. Patent ... the patent eligibility criteria established by the Supreme Court,s ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former ... of the University of North Carolina Kenan-Flagler Business School effective June ... UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes and ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... to announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. ... years, is proud to add Target to its list of well-respected retailers. This ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016   Acuant ... and verification solutions, has partnered with RightCrowd ... solutions for Visitor Management, Self-Service Kiosks and ... products that add functional enhancements to existing ... corporations and venues with an automated ID ...
(Date:6/20/2016)... June 20, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring ... involved, it has secured the final acceptance by ... for Managed Access Systems (MAS) installed. Furthermore, Securus ... to be installed by October, 2016. MAS distinguishes ...
(Date:6/9/2016)... -- Perkotek an innovation leader in attendance control systems is proud to announce the introduction ... to make sure the right employees are actually signing in, and to even control ... ... ... ...
Breaking Biology News(10 mins):